Technical analysis of Connect Biopharma Holdings Limited (CNTB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody.
Price Performance
| 1 month | -48.97% |
| 3 months | -38.00% |
| Year-to-date | -56.03% |
| 1 year | -22.98% |
| 3 years | +82.35% |
| 5 years | -94.62% |
52-Week Range
| 52-week High | $3.82 |
| 52-week Low | $1.06 |
| Avg Volume (90d) | 717K |
Technical Indicators
| SMA 50 | $2.19 |
| SMA 200 | $2.43 |
| Beta | -0.21 |
| 30-day Volatility (annualised) | 176.3% |
| Price vs SMA 50 | -43.5% |
| Price vs SMA 200 | -49.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.71 | |
| 2025-11 | $2.81 | +64.3% |
| 2025-12 | $2.82 | +0.4% |
| 2026-01 | $2.40 | -14.9% |
| 2026-02 | $2.47 | +2.9% |
| 2026-03 | $2.62 | +6.1% |
| 2026-04 | $2.47 | -5.7% |
| 2026-05 | $2.49 | +0.8% |
| 2026-06 | $2.38 | -4.4% |
| 2026-07 | $2.02 | -15.1% |
| 2026-08 | $2.20 | +8.9% |
| 2026-09 | $1.24 | -43.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $0.05 | $157M |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | $0.10 | $672M |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.24 |
| Market Cap | $78M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.31 |
| EV / EBITDA | -2.19 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 3.74 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -5.94 |